Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma

Radiother Oncol. 2021 Apr:157:219-224. doi: 10.1016/j.radonc.2021.01.030. Epub 2021 Feb 4.

Abstract

Purpose: To compare the adverse side effects of fractionated stereotactic photon beam radiotherapy (fSRT) with proton beam radiotherapy (PBR) in patients with uveal melanoma (UM).

Methods: A retrospective study investigating 306 UM patients treated with fSRT (N=153) by the Rotterdam Ocular Melanoma Study group (ROMS), The Netherlands, between 1999-2014 or with PBR (N=153) at the Royal Liverpool University Hospital and the Clatterbridge Cancer Centre, Bebington, United Kingdom, between 1993-2014. The tumours treated with fSRT were matched with tumours treated with PBR based on sex, left or right eye, TNM classification, posterior margin ≤ or > 3mm of the fovea and of the optic disc.

Results: The five-year actuarial rates of tumour recurrence were 4.5% for fSRT and 6.1% for PBR. For fSRT and PBR, the five-year actuarial rates of maculopathy were 14.9% and 12.4%, and for vitreous haemorrhage were 29.4% and 4.7%, respectively. Only vitreous haemorrhage (HR: 0.19, 95% CI: 0.07-0.56) was more common after fSRT compared to PBR. Overall, larger tumours were risk factors for maculopathy and secondary enucleation.

Conclusions: Both treatments have excellent local tumour control. In matched groups, vitreous haemorrhage was the only adverse side effect showing a significant difference between groups.

Keywords: Fractionated stereotactic photon beam radiotherapy; Local tumour control; Proton beam radiotherapy; Side effects; Uveal melanoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Eye Enucleation
  • Humans
  • Melanoma* / radiotherapy
  • Neoplasm Recurrence, Local
  • Netherlands
  • Protons
  • Radiosurgery*
  • Retrospective Studies
  • United Kingdom
  • Uveal Neoplasms* / radiotherapy

Substances

  • Protons

Supplementary concepts

  • Uveal melanoma